Brief: Optinose Announces FDA Acceptance Of Supplemental New Drug Application For XHANCE
04/05/2023 12:05
May 4 (Reuters) - OptiNose Inc OPTN.O :
* OPTINOSE ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG
APPLICATION FOR XHANCE
* OPTINOSE INC - SNDA HAS BEEN ASSIGNED A PRESCRIPTION DRUG
USER
FEE ACT (PDUFA) TARGET GOAL DATE OF DECEMBER 16, 2023
Source text for Eikon: ID:nGNX2mdqN
Further company coverage: OPTN.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on OptiNose
See all newsOptiNose Inc reports results for the quarter ended March 31 - Earnings Summary
OptiNose Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: OptiNose Q4 Income From Operations USD 354 Thousand
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx